source
- Eli Lilly's retatrutide shows strong weight loss but no clear heart risk reduction in Phase 3 trialEli Lilly released new data from a Phase 3 trial of retatrutide, its next‑generation obesity drug. The study enrolled nearly 2,000 participants with severe obesity and existing heart disease, some…
- EMA moves quickly to enforce clinical trial result reporting across EuropeThe European Medicines Agency announced new measures aimed at ensuring that results of clinical trials are posted publicly in line with legal obligations. The steps follow an analysis that found f…